Skip to content

T-Port to apply Duodopa.

Transcutaneous port (T-Port) for gastrostomy use in combination with Duodopa.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23186
Enrollment
10
Registered
2007-03-13
Start date
2007-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Parkinson's disease (NLD: ziekte van Parkinson)

Interventions

Insertion in abdominal wall titanium T-Port en insertion of duodenum tube.

Sponsors

TransCutan AB
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinical diagnosis of advanced Parkinson's disease. On/off phenomena leading to severe disability which can not be regulated by the normal oral drug schemes. A clinical indaction for duodenum Duodopa tretament should have been made by the treating physician.

Exclusion criteria

Exclusion criteria: 1. Non-responsiveness to levodopa substitution therapy; 2. Deformities abdominal wall.

Design outcomes

Primary

MeasureTime frame
1. To assess the safety and tolerability: a. Adverse event monitoring; b. Tolerability assessed by number of subjects who complete the 6 months of treatment; c. Acceptance of the T-Port by the patients; In addition: 2. Physical examination, including weight; 3. Vital signs systolic/diastolic blood pressure and pulse rate; 4. Concomitant medication usage; 5. Monitoring complications of the infusion device.

Contacts

Public ContactK.L. Leenders

Hanzeplein 1

k.l.leenders@neuro.umcg.nl+31 50 361 2175

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)